

# Principles and Practice of Clinical Research

A Global Journal in Clinical Research



# PPCR

ISSN: 2378-1890

## Costs and economic impacts of type-1 diabetes from the dominican patient perspective

A. Gutiérrez<sup>1\*</sup>, C. Vargas<sup>1</sup>, D. Crespo<sup>1</sup>, N. Romero<sup>2</sup>, F. Colón<sup>3</sup>, S. Gresse Júnior<sup>4</sup>

\*Corresponding author: Anthony Gutiérrez MD. Pontificia Universidad Católica Madre y Maestra, Santiago de los Caballeros, Km 1 1/2 Autopista Duarte, Santiago, Dominican Republic. E-mail: anthjgutierrez@gmail.com.

Rest of author's affiliation at the end of the manuscript.

Received January 29, 2021; accepted April 28, 2021; published July 11, 2021.

DOI: <http://dx.doi.org/10.21801/ppcrj.2021.72.1>

### APPENDICES

#### A. Micro costing analysis

TABLE 1. FIXED DOSE TREATMENT: COST OF MEDICATIONS AND SUPPLIES

Product	Abbr.	Amount/day	Amount/month	Cost/unit.	Cost/month
NPH <sup>a</sup>	Nph	17.5 U	525 U*	110 DOP /10ml	110 DOP
Regular insulin <sup>a</sup>	Ri	17.5 U	525 U*	110 DOP /10ml	110 DOP
Syringes 1ml/6mm <sup>a, b</sup>	S1	2 units	60 units	12 DOP	720 DOP
Syringes 1ml/8mm <sup>a, b</sup>	S2	2 units	60 units	8 DOP	480 DOP
NPH <sup>b</sup>	Nph	17.5 U	525 U*	440 DOP/10ml	440 DOP
Regular <sup>b</sup>	Ri	17.5 U	525 U*	440 DOP/10ml	440 DOP
Test strips 1 <sup>a</sup>	Ts1	4 units	120 units	24.70 DOP	2,694 DOP
Test strips 2 <sup>a</sup>	Ts2	4 units	120 units	52.30 DOP	6,276 DOP
Test strips 3 <sup>a</sup>	Ts3	4 units	120 units	26.64 DOP	3,196 DOP
Test strips 4 <sup>a</sup>	Ts4	4 units	120 units	26.20 DOP	2,144 DOP
Generic lancets <sup>a</sup>	L	4 units	120 units	4.65 DOP	558 DOP

<sup>a</sup> Cost from public perspective

<sup>b</sup> Cost from private perspective

\*This quantity is contained in a single 10 ml package

BOX 1. FIXED DOSE TREATMENT: MICRO-COSTING ANALYSIS

$$\text{Total Monthly Cost (TMC)} = \sum [\text{Monthly product amount}(m) \times \text{Unitary cost}(u)]$$

$$\text{TMC} = [(NPHm \times NPHu) + (Rim \times Riu) + (S2m \times S2u) + (Ts1m \times Ts1u) + (Lm \times Lu)]$$

TMC - Public Perspective

$$\text{TMC} = [(1 \times 110 \text{ DOP}) + (1 \times 110 \text{ DOP}) + (60 \times 8 \text{ DOP}) + (120 \times 24.70 \text{ DOP}) + (120 \times 4.65 \text{ DOP})]$$

$$\text{TMC} = [110 \text{ DOP} + 110 \text{ DOP} + \$480 + 2,964 \text{ DOP} + 558 \text{ DOP}]$$

$$\text{TMC} = 4,222.00 \text{ DOP} / \text{USD } 72.74$$

TMC - Private Perspective

$$\text{TMC} = [(1 \times 440 \text{ DOP}) + (1 \times 440 \text{ DOP}) + (60 \times 8 \text{ DOP}) + (120 \times 24.70 \text{ DOP}) + (120 \times 4.65 \text{ DOP})]$$

$$\text{TMC} = [440 \text{ DOP} + 440 \text{ DOP} + 480 \text{ DOP} + 2,964 \text{ DOP} + 558 \text{ DOP}]$$

$$\text{TMC} = 4,882.00 \text{ DOP} / \text{USD } 84.11$$

Ri: Regular; S2: Syringes 2; Ts1: Test strips1; L: Generic lancets

TABLE 2. MULTIPLE DAILY INJECTIONS TREATMENT: COST OF MEDICATIONS AND SUPPLIES

Product	Abbr.	Amount/day	Amount/Month	Cost/unit.	Cost/Month
Glargine (3ml/pen) <sup>a</sup>	IGlar	18 U	540 U (2 pen)	1,447 DOP/pen	2,894 DOP
Degludec (3ml/pen) <sup>a</sup>	IDeg	18 U	540 U (2 pen)	2,206 DOP/pen	4,412 DOP
Glulisine (3ml/pen) <sup>a</sup>	IGlu	15 U	450 U (2 pen)	1,559 DOP/pen	3,118 DOP
Aspart (3ml/pen) <sup>a</sup>	IAsp	15 U	450 U (2 pen)	1,315 DOP/pen	2,630 DOP
Detemir (3ml/pen) <sup>a</sup>	IDet	18 U	540 U (2 pen)	1,460 DOP/pen	2,920 DOP
Syringes 1 <sup>a</sup>	S1	6 units	180 units	20.30 DOP	3,654 DOP
Syringes 2 <sup>a</sup>	S2	6 units	180 units	21.09 DOP	3,780 DOP
Test strips 1 <sup>a</sup>	Ts1	7 units	210 units	24.70 DOP	5,187 DOP

Test strips 2 <sup>a</sup>	Ts2	7 units	210 units	52.30 DOP	10,983 DOP
Test strips 3 <sup>a</sup>	Ts3	7 units	210 units	26.64 DOP	3,196 DOP
Test strips 4 <sup>a</sup>	Ts4	7 units	210 units	26.20 DOP	5,594 DOP
Generic lancets <sup>a</sup>	L	7 units	210 units	4.65 DOP	976 DOP

<sup>a</sup> Cost from private perspective

BOX 2. MULTIPLE DAILY INJECTIONS TREATMENT: MICROCASTING ANALYSIS

$$\text{Total Monthly Cost (TMC)} = \sum [(Monthly Product Amount(m) \times Unitary cost(u))]$$

$$\text{TMC Option \#1} = [(IAspm \times IAspu) + (IDegm \times IDegu) + (S1m \times S1u) + (Ts1m \times Ts1u) + (Lm \times Lu)]$$

$$\text{TMC \#1} = [(2 \times 1,315 \text{ DOP}) + (2 \times 2,206 \text{ DOP}) + (180 \times 20.30 \text{ DOP}) + (210 \times 24.70 \text{ DOP}) + (210 \times 4.65 \text{ DOP})]$$

$$\text{TMC \#1} = [(2,630 \text{ DOP}) + (4,412 \text{ DOP}) + (3,654 \text{ DOP}) + (5,187 \text{ DOP}) + (976.50 \text{ DOP})]$$

$$\text{TMC \#1} = 16,859.50 \text{ DOP / USD } 290.47$$

$$\text{TMC Option \#2} = [(IGlum \times IGluu) + (IGlarm \times IGlaru) + (S1m \times S1u) + (Ts1m \times Ts1u) + (Lm \times Lu)]$$

$$\text{TMC \#2} = [(2 \times 1,559 \text{ DOP}) + (2 \times 1,447 \text{ DOP}) + (180 \times 20.30 \text{ DOP}) + (210 \times 24.70 \text{ DOP}) + (210 \times 4.65 \text{ DOP})]$$

$$\text{TMC \#2} = [(3,118 \text{ DOP}) + (2,894 \text{ DOP}) + (3,654 \text{ DOP}) + (5,187 \text{ DOP}) + (976.50 \text{ DOP})]$$

$$\text{TMC \#2} = 15,829.50 \text{ DOP / USD } 272.73$$

$$\text{TMC Option \#3} = [(IGlum \times IGluu) + (IDetm + IDetu) + (S1m \times S1u) + (Ts1m \times Ts1u) + (Lm \times Lu)]$$

$$\text{TMC \#3} = [(2 \times 1,559 \text{ DOP}) + (2 \times 1,460 \text{ DOP}) + (180 \times 20.30 \text{ DOP}) + (210 \times 24.70 \text{ DOP}) + (210 \times 4.65 \text{ DOP})]$$

$$\text{TMC \#3} = [(3,118 \text{ DOP}) + (2,920 \text{ DOP}) + (3,654 \text{ DOP}) + (5,187 \text{ DOP}) + (976.50 \text{ DOP})]$$

$$\text{TMC \#3} = 15,855.50 \text{ DOP / USD } 273.18$$

IAsp: Aspart; IDeg: Degludec; IDet: Detemir; S1: Syringes 1; Ts1: Test strips 1; L: Generic Lancets; IGlu: Insulin IGlar: Insulin Glargine

TABLE 3. CONTINUOUS SUBCUTANEOUS INSULIN INFUSION: COST OF MEDICATION AND SUPPLIES

Product	Abbr.	Amount/day	Amount/month	Cost/unit.	Cost/month
Insulin pump <sup>a</sup>	Pump	-	-	337,480 DOP	-
Sensor transmitter <sup>a</sup>	Tran	-	-	45,430 DOP	-
Sensors (disposable) <sup>a</sup>	Sen	-	1 package	41,890 DOP	41,890 DOP
Reservoir (disposable) <sup>a</sup>	Res	-	1 package	10,841 DOP	10,841 DOP
Insulin <sup>a</sup>	IGlu	-	1 vial - IGlu	1,559 DOP	1,559 DOP
Test strips 1 <sup>a</sup>	Ts1	4 units	120 units	24.70 DOP	2,694 DOP
Test strips 2 <sup>a</sup>	Ts2	4 units	120 units	52.30 DOP	6,276 DOP
Test strips 3 <sup>a</sup>	Ts3	4 units	120 units	26.64 DOP	3,196 DOP
Test strips 4 <sup>a</sup>	Ts4	4 units	120 units	26.20 DOP	3,144 DOP
Generic lancets <sup>a</sup>	L	4 units	120 units	4.65 DOP	558 DOP

<sup>a</sup> Cost from private perspective

BOX 3. CONTINUOUS SUBCUTANEOUS INSULIN INFUSION: MICROCASTING ANALYSIS

$$\text{Total Fixed cost (TFC)} = \sum [(Device(u) \times Cost\ of\ device)]$$

$$TFC = [(Pump_u \times Pump\$) + (Tran_u \times Tran\$)]$$

$$TFC = [(1 \times 337,480\ DOP) + (1 \times 45,430\ DOP)]$$

$$TFC = 382,910.00\ DOP / USD\ 6,597.35$$

$$\text{Total Monthly cost (TMC)} = \sum [(Monthly\ Product\ Amount(m) \times Unitary\ cost(u)]$$

$$TMC = [(Sen_m \times Sen_u) + (Res_m \times Res_u) + (IGlu_m \times IGlu_u) + (Ts1_m \times Ts1_u) + (L_m \times L_u)]$$

$$TMC = [(1 \times 41,890\ DOP) + (1 \times 10,841\ DOP) + (1 \times 1,559\ DOP) + (120 \times 24.70\ DOP) + (120 \times 4.65\ DOP)]$$

$$TMC = 57,812.00\ DOP / USD\ 996.07$$

Pump: Insulin Pump, Tran: Sensor transmitter, Sen: Sensors (disposable), Res: Reservoir (disposable), IGlu: Glulisine, Ts1: Test strips1, L: Generic lancets

**B. List of abbreviations**

ABBR.	MEANING	ABBR.	MEANING
$\Sigma$	Summation (symbol)	<b>NPH</b>	NPH insulin®
CSII	Continuous subcutaneous insulin infusion	<b>NPHm</b>	NPH Insulin - monthly product amount
DOP	Dominican pesos	<b>NPHu</b>	NPH Insulin - Unitary cost
DQoL	Diabetes Quality of life	<b>PUMP</b>	Insulin pump
DR	Dominican Republic	<b>QoL</b>	Quality of Life
FD	Fixed dose	<b>Res</b>	Reservoir (dischargeable)
GDP	Gross domestic product	<b>Resm</b>	Reservoir - monthly product amount
HbA1c	Glycated hemoglobin	<b>Resu</b>	Reservoir - Unitary cost
HEOR	Health Economics and Outcomes Research	<b>Ri</b>	Regular insulin
HMO	Health maintenance organization	<b>Rim</b>	Regular insulin - monthly product amount
HRQoL	Health-related quality of life	<b>Riu</b>	Regular insulin - Unitary cost
HTA	Health technology assessment	<b>S1</b>	Syringe option 1
IAsp	Insulin aspart	<b>S1m</b>	Syringe option 1 - monthly product amount
IAspm	Insulin aspart - monthly product amount	<b>S1u</b>	Syringe option 1 - Unitary cost
laspu	Insulin aspart - Unitary cost	<b>S2</b>	Syringe option 2
IDeg	Insulin degludec	<b>S2m</b>	Syringe option 2 - monthly product amount
IDegm	Insulin degludec - monthly product amount	<b>S2u</b>	Syringe option 2 - Unitary cost
IDegu	Insulin degludec - Unitary cost	<b>SD</b>	Standard deviation
IDet	Insulin detemir	<b>Sen</b>	Sensors (dischargeable)
IDetm	Insulin detemir - monthly product amount	<b>Senm</b>	Sensors - monthly product amount
IDetu	Insulin detemir - Unitary cost	<b>Senu</b>	Sensors - Unitary cost
IGlar	Insulin glargine	<b>T1D</b>	Type-1 diabetes
IGlarm	Insulin glargine - monthly product amount	<b>TFC</b>	Total Fixed costs
IGlaru	Insulin glargine - Unitary cost	<b>TMC</b>	Total Monthly cost
IGlu	Insulin glulisine	<b>Tran</b>	Sensor transmitter
IGlum	Insulin glulisine - monthly product amount	<b>Ts1</b>	Test strips option 1
IGluu	Insulin glulisine - Unitary cost	<b>Ts1m</b>	Test strips option 1 - monthly product amount
L	Generic lancets	<b>Ts1u</b>	Test strips option 1 - Unitary cost
LATAM	Latin-American	<b>Ts2</b>	Test strips option 2
Lm	Generic Lancets - monthly product amount	<b>Ts2u</b>	Test strips option 2 - Unitary cost
Lu	Generic Lancets - Unitary cost	<b>Ts3</b>	Test strips option 3
MDI	Multiple daily injections	<b>Ts4</b>	Test strips option 4
MHI	Mean household income	<b>USD</b>	United States dollar
NMW	National minimum wage	<b>WB</b>	World Bank